A five‐gene signature may associate with central nervous system dissemination in adult acute lymphoblastic leukemia
Hematological Oncology · 2023
DOI: 10.1002/hon.3136 ↗At a glance
Leserbrief in Hematological Oncology, 2023. Written by Maria Rosaria Sapienza and 6 co-authors. Institution: Division of Hematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy. Major MEDLINE topics: Central Nervous System Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Cited 4 times so far (Crossref); 11 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Associazione Italiana Ricerca sul Cancro, Special 5x1000 Program Metastases, Milano.
Abstract (original language)
The outcome of patients with acute lymphoblastic leukemia (ALL) has progressively improved over the years thanks to a more precise diagnostic and prognostic work ‐ up at presentation based on biological and molecular features, to the increasing use of targeted therapies and to a more personalized follow ‐ up and management of patients. 1,2 Nonetheless, refractory/relapsed cases have an aggressive clinical course and a poor prognosis. At a time when the prognostic likelihood of adult ALL is improving, an extramedullary dissemination to the central nervous system (CNS) is becoming an increasing unmet clinical need. 1 CNS localization represents a primary cause of treatment failure and mortality among adult ALL patients. 1 A sizable proportion of ALL patients develop a CNS dissemination: in about 3%–5% of patients it can be detected already at diagnosis while in 30%–40% of patients it develops during the course of the disease. 1 Irrespective of the initial CNS status, all therapeutic schemes include CNS prophylaxis, mostly based on the combined use of systemic and intrathecal chemotherapy. 1 The molecular mechanisms underlying a dissemination to the CNS are still poorly understood and molecular markers predicting CNS involvement in patients with adult ALL are currently lacking. These markers would be critical to implement a tailored therapy that could guide a more effective treatment in patients at a higher risk of CNS localization, in order to prevent a CNS relapse, and to limit the degree of CNS prophylaxis in patients with a low risk of CNS involvement.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of Hematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy.
- Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
- Department of Pathology, Boston Children's Hospital, Boston, MA, USA.
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
ORCID profiles: Maria Rosaria Sapienza
Funding
- Associazione Italiana Ricerca sul Cancro
- Special 5x1000 Program Metastases
- Milano
Cite
APA
Sapienza, M. R., Chiaretti, S., Cardinali, D., Mazzara, S., Chiarle, R., Foà, R., & Pileri, S. A. (2023). A five‐gene signature may associate with central nervous system dissemination in adult acute lymphoblastic leukemia. Hematological Oncology. https://doi.org/10.1002/hon.3136
Vancouver
Sapienza MR, Chiaretti S, Cardinali D, Mazzara S, Chiarle R, Foà R, et al. A five‐gene signature may associate with central nervous system dissemination in adult acute lymphoblastic leukemia. Hematological Oncology. 2023. doi:10.1002/hon.3136
BibTeX
@article{Sapienza2023,
author = {Sapienza, Maria Rosaria and Chiaretti, Sabina and Cardinali, Deborah and Mazzara, Saveria and Chiarle, Roberto and Foà, Robin and Pileri, Stefano A},
title = {A five‐gene signature may associate with central nervous system dissemination in adult acute lymphoblastic leukemia},
journal = {Hematological Oncology},
year = {2023},
doi = {10.1002/hon.3136}
}
EUVIMED